Several genes and gene products were identified as targets of miR-223, including NLRP3, IL18, IL1β, DNA methyltransferase 1, and checkpoint kinase-1, signifying its potential use as a cancer-specific diagnostic biomarker and therapy. This evidence concerns the gene IL18 and cancer.